Document Detail

Determination of plasma soluble fibrin using a new ELISA method in patients with disseminated intravascular coagulation.
MedLine Citation:
PMID:  8619398     Owner:  NLM     Status:  MEDLINE    
We measured plasma levels of soluble fibrin (SF) in 98 patients suspected of having disseminated intravascular coagulation (DIC) using a newly developed enzyme-linked immunosorbent assay (ELISA) and investigated the correlations between SF determinations and measurements of other hemostatic molecular markers to determine the diagnostic usefulness of determinations of SF. Patients were classified into four groups according to their clinical and laboratory findings: overt DIC (n =33), subclinical DIC (n =23) hypercoagulability (n =22), and non-DIC (n =20). SF levels were significantly higher in patients with overt DIC compared with the other three groups and were significantly higher in the subclinical DIC and hypercoagulability groups compared with the non-DIC patients. SF levels increased significantly with each increase in the clinical stage. Although levels of thrombin-antithrombin III complex (TAT), prothrombin fragment 1 + 2 (PF 1+2), cross-linked fibrin degradation products (XDP), and plasmin-antiplasmin complex (PAP) were significantly increased in patients with overt DIC compared with non-DIC patients, the values of these hemostatic molecular markers did not consistently show an increase in association with advances in the disease stage. Plasma levels of SF in patients with overt DIC showed a positive correlation with levels of TAT, XDP,and FDP(E), but not with PF1+2 and PAP. Analysis of receiver-operating characteristic curves showed that the sensitivity and specificity of SF were similar to those of XDP for diagnosis of DIC. The sensitivity and specificity of SF for diagnosis of overt DIC were both above 90% when the cut-off value was set at 65 mu g/ml.plasma levels of SF were also increased in patients with extravascular fibrin formation without DIC. Our findings suggest that measurement of plasma levels of SF by this ELISA method is useful for the diagnosis of DIC and the evaluation of the patient's clinical status.
K Okajima; M Uchiba; K Murakami; H Okabe; K Takatsuki
Related Documents :
16085558 - Disseminated intravascular coagulation complicating acute lymphoblastic leukemia: a stu...
22125658 - Frequency of contact allergens in pediatric patients with atopic dermatitis.
21980798 - Clinical relevance of non-grass pollens respiratory allergies in italy and effects of s...
10467278 - Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolon...
11351148 - Beneficial effects of a novel ih636 grape seed proanthocyanidin extract in the treatmen...
7528178 - The effect of extracorporeal shock wave lithotripsy on pancreatic enzymes.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  American journal of hematology     Volume:  51     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  1996 Mar 
Date Detail:
Created Date:  1996-06-11     Completed Date:  1996-06-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  186-91     Citation Subset:  IM    
Department of Laboratory Medicine, Kumamoto Univeristy Medical School, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acid Sequence
Antithrombin III / analysis
Disseminated Intravascular Coagulation / blood*,  diagnosis*
Enzyme-Linked Immunosorbent Assay / methods*
Fibrin / analysis*,  chemistry
Fibrin Fibrinogen Degradation Products / analysis
Molecular Sequence Data
Peptide Fragments / analysis
Peptide Hydrolases / analysis
Prothrombin / analysis
ROC Curve
Sensitivity and Specificity
Reg. No./Substance:
0/Fibrin Fibrinogen Degradation Products; 0/Peptide Fragments; 0/antithrombin III-protease complex; 0/prothrombin fragment 1.2; 9000-94-6/Antithrombin III; 9001-26-7/Prothrombin; 9001-31-4/Fibrin; EC 3.4.-/Peptide Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
Next Document:  Clinical correlates among 49 families with hemophilia A and factor VIII gene inversions.